Avalo Therapeutics posts new investor presentation

Avalo Therapeutics, Inc. filed a current report to note that on October 10, 2025 it posted an updated investor presentation on its website.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. filed a current report to note that on October 10, 2025 it posted an updated investor presentation on its website. This presentation, attached as Exhibit 99.1, is intended for use from time to time in meetings with investors and is incorporated into the report by reference.

The filing does not describe new financial results or major transactions, but formally makes the investor presentation part of Avalo’s public disclosure record for shareholders and analysts who follow the company.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalo Therapeutics (AVTX) disclose in this 8-K?

Avalo Therapeutics, Inc. disclosed that it posted an updated investor presentation on its website on October 10, 2025, and attached it as Exhibit 99.1 for reference.

What is included as Exhibit 99.1 in Avalo Therapeutics’ 8-K?

Exhibit 99.1 to the 8-K is an updated investor presentation that Avalo Therapeutics plans to use from time to time in meetings with investors.

Does this Avalo Therapeutics (AVTX) 8-K announce new financial results?

No, this 8-K describes an updated investor presentation and its availability, rather than reporting new financial results or major transactions.

How will Avalo Therapeutics use the updated investor presentation?

Avalo Therapeutics states that the Investor Presentation will be used from time to time in meetings with investors, and has been made publicly available and incorporated by reference.

Who signed the Avalo Therapeutics (AVTX) 8-K?

The 8-K was signed on behalf of Avalo Therapeutics, Inc. by Christopher Sullivan, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/10/2025 - 07:01 AM Learn about SEC filing dates

0001534120false00015341202025-10-102025-10-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2025

AVALO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)  

Delaware

(State or other jurisdiction of incorporation)

001-37590						45-0705648
(Commission File Number)						(IRS Employer Identification No.)

1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (410) 522-8707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 Par Value			AVTX			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01    Other Events.

On October 10, 2025, Avalo Therapeutics, Inc. posted on its website an updated investor presentation (the “Investor Presentation”). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits:

Exhibit No.						Description
99.1						Investor Presentation.
104						The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									AVALO THERAPEUTICS, INC.
Date: October 10, 2025						By:			/s/ Christopher Sullivan
									Christopher Sullivan
									Chief Financial Officer

2